<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929496</url>
  </required_header>
  <id_info>
    <org_study_id>EASY-PREDICT pilot study</org_study_id>
    <nct_id>NCT04929496</nct_id>
  </id_info>
  <brief_title>Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study</brief_title>
  <acronym>EASY-PREDICT</acronym>
  <official_title>Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: the PREDICT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opsens Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Chair on Interventional Cardiology and Transradial Approach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the use of physiology parameters as guidance&#xD;
      post-percutaneous coronary interventions (PCI) is associated with less risks of target vessel&#xD;
      failure (TVF) and angina-related events than standard angiographic guidance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fractional flow reserve (FFR) measurement involves determining the ratio between the maximum&#xD;
      achievable blood flow in a diseased coronary artery and the theoretical maximal flow in a&#xD;
      normal coronary artery. An FFR of 1.0 is widely accepted as normal. An FFR value less than or&#xD;
      equal to 0.80 is generally considered to be associated with myocardial ischemia.&#xD;
&#xD;
      FFR is easily measured during routine coronary angiography by using a pressure wire to&#xD;
      calculate the ratio between coronary pressure distal to a coronary artery stenosis and aortic&#xD;
      pressure under conditions of maximum myocardial hyperemia. this ratio represents the&#xD;
      potential decrease in coronary flow distal o the coronary stenosis. Recently, other&#xD;
      physiology ratios called non-hyperemic ratios (NHPR) have been developed.&#xD;
&#xD;
      Both types of physiology measures (FFR and NHPR) have been increasingly used in cardiac&#xD;
      catheterization laboratories as a diagnostic tool. They provide a quantitative assessment of&#xD;
      the functional severity of a coronary artery stenosis identified during coronary angiography&#xD;
      and cardiac catheterization. However, they are underutilized as tools for the assessment of&#xD;
      success of coronary interventions.&#xD;
&#xD;
      The PREDICT study is a pilot study which aims to prospectively determine whether post-PCI&#xD;
      physiology guidance is associated with better clinical outcomes than standard angiographic&#xD;
      guidance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Target Vessel Failure</measure>
    <time_frame>within 12 months after index PCI;</time_frame>
    <description>as the composite of cardiac death, lesion-related MI and target vessel revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of angina-related events</measure>
    <time_frame>within 12 months after index PCI;</time_frame>
    <description>defined as hospitalization for unstable angina and unsolicited medical visits for angina</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final post-PCI pressure ratio values according to lesion location and intervened vessels</measure>
    <time_frame>Post-randomization after stent implantation (&lt; 1 hour)</time_frame>
    <description>In the Physiology group, final pressure ratio (Pd/Pa) values will be collected immediately after randomization, and if further intervention is performed, before completing the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final post-PCI FFR values according to lesion location and intervened vessels</measure>
    <time_frame>Post-randomization after stent implantation (&lt; 1 hour)</time_frame>
    <description>In the Physiology group, final FFR values will be collected immediately after randomization, and if further intervention is performed, before completing the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final post-PCI dPR values according to lesion location and intervened vessels</measure>
    <time_frame>Post-randomization after stent implantation (&lt; 1 hour)</time_frame>
    <description>In the Physiology group, final dPR values will be collected immediately after randomization, and if further intervention is performed, before completing the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final post-PCI physiology pullback curves according to lesion location and intervened vessels</measure>
    <time_frame>Post-randomization after stent implantation (&lt; 1 hour)</time_frame>
    <description>In the Physiology group, final physiology pullback curves will be collected immediately after randomization, and if further intervention is performed, before completing the intervention if possible.&#xD;
Physiology pullback refers to either hyperemic or non-hyperemic pullback.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of unstable angina requiring hospitalization or unsolicited medical visits</measure>
    <time_frame>within 12 months of index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of individual components of MACE</measure>
    <time_frame>within 12 months of index procedure</time_frame>
    <description>including all-cause mortality, MI, TVR and any revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Chest Pain</condition>
  <arm_group>
    <arm_group_label>Angiographical guidance only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-PCI FFR guidance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-PCI Fractional Flow Reserve and non-hyperemic pressure ratios measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>post-PCI FFR</intervention_name>
    <description>final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.</description>
    <arm_group_label>Post-PCI FFR guidance</arm_group_label>
    <other_name>Fractional Flow Reserve</other_name>
    <other_name>Non-hyperemic pressure ratios</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient referred for diagnostic coronary angiography and / or possible PCI in&#xD;
             native coronary vessels.&#xD;
&#xD;
          -  Successful (&lt; 30% diameter stenosis and normal TIMI 3 flow post-stenting) and&#xD;
             uncomplicated PCI&#xD;
&#xD;
          -  All treated lesions stented with drug-eluting stents (except side-branches of&#xD;
             bifurcations)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lesion in saphenous vein or arterial grafts&#xD;
&#xD;
          -  Allergy to aspirin, thienopyridines or ticagrelor precluding treatment for 30 days&#xD;
&#xD;
          -  Sub-optimal PCI result ( &gt;30% residual diameter stenosis and/or &lt;TIMI3 flow) or&#xD;
             peri-procedural complications&#xD;
&#xD;
          -  Acute ST-Elevation MI (culprit lesion)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier F. Bertrand, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Chair on Interventional Cardiology and Transradial Approach</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier F. Bertrand, MD, PhD</last_name>
    <phone>4186568711</phone>
    <phone_ext>5947</phone_ext>
    <email>olivier.bertrand@fmed.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Jadin</last_name>
    <phone>4186568711</phone>
    <email>michele.jadin@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IUCPQ - Laval Hospital</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier F Bertrand, MD PhD</last_name>
      <phone>418 656 8711</phone>
      <email>olivier.bertrand@crhl.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Olivier F Bertrand, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomas Cieza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Poirier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Olivier F. Bertrand</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Post-PCI FFR</keyword>
  <keyword>Angiography</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

